Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 7 for:    oleogel-s10

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12) (BSG-12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01807650
Recruitment Status : Completed
First Posted : March 8, 2013
Results First Posted : July 19, 2018
Last Update Posted : July 19, 2018
Sponsor:
Information provided by (Responsible Party):
Amryt Pharma ( Birken AG )

Brief Summary:
The main purpose of this phase III clinical trial was to show safety and efficacy of Oleogel-S10 in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.

Condition or disease Intervention/treatment Phase
Wounds Drug: Oleogel-S10, non-adhesive wound dressing Device: Non-adhesive wound dressing only Phase 3

Detailed Description:

Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in participants with skin lesions. Especially the results in a previous study with STSG donor sites suggested that Oleogel-S10 should be efficacious and safe in the treatment of superficial wounds.

The present phase III clinical trial in STSG donor sites was initiated to demonstrate wound healing progress, i.e., the time to healing and the grade of epithelialization of the wound.

In this study, STSG donor sites were separated into 2 wound halves. Randomly assigned, 1 wound half was treated with Oleogel-S10 and non-adhesive wound dressing, the other wound half with non-adhesive wound dressing only (standard of care).

Wound healing progress was documented by photos which were assessed by expert reviewers blinded to the treatment of the wound halves.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites
Study Start Date : March 2013
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oleogel-S10, non-adhesive wound dressing
A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Drug: Oleogel-S10, non-adhesive wound dressing
1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Other Name: Episalvan®

Non-adhesive wound dressing only
A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
Device: Non-adhesive wound dressing only
Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Other Name: Mepilex®




Primary Outcome Measures :
  1. Intra-individual Difference in Time to Wound Closure [ Time Frame: 2 to 4 weeks ]
    Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing only. Independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound half that were taken before start of treatment, during wound dressing changes and at the end of treatment. Difference in time to wound closure was calculated for every individual participant as [time taken for wound half treated with Oleogel-S10 to close] - [time taken for wound half treated with non-adhesive wound dressing to close], i.e., results below 0 indicate earlier wound closure of Oleogel-S10 treatment. The overall mean difference in time to wound closure was calculated based on all mean differences in time to wound closure of individual participants. Hence, primary outcome data derived from mean difference in time to wound closure by participant.


Secondary Outcome Measures :
  1. Time From Surgery Until Wound Closure is Achieved [ Time Frame: 2 to 4 weeks ]
    Time from surgery until wound closure is achieved, separately for wound halves treated with Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only. While outcome measure 1 (intra-individual difference in time to wound closure) was calculated based on mean intra-individual difference in time to wound closure in 110 participants with missing values replaced by a value of 0, for outcome measure 2 missing values were not replaced. For 2 of the 110 wounds data were missing, thus the reported values are calculated from 108 STSG donor site wound halves by intervention (Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only).

  2. Percentage of Participants With Earlier Healing [ Time Frame: 2 to 4 weeks ]
    Percentage of participants with earlier healing of wound area treated with Oleogel-S10 and non-adhesive wound dressing compared to non-adhesive wound dressing only

  3. Percentage of Participants With Wound Closure at Different Time Points [ Time Frame: 2 to 4 weeks ]
    For separate time points (Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28), the frequencies of wound areas which have reached wound closure were calculated.

  4. Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator [ Time Frame: 2 to 4 weeks ]
    A study team member assessed the progress of wound healing by treatment regimen and noted the degree of epithelialization (expressed in percent of the original wound size) at wound dressing changes on Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28.

  5. Likert Scale Rating of Efficacy [ Time Frame: 2 to 4 weeks ]
    Participants and investigators were asked to grade the efficacy of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only on a 5-point Likert scale (treatment with Oleogel-S10 is much more effective, treatment with Oleogel-S10 is more effective, both treatments have the same efficacy, non-adhesive wound dressing only is more effective, non-adhesive wound dressing only is much more effective).

  6. Cosmetic Outcome at 3 and 12 Months After Surgery, Respectively [ Time Frame: 3 months and 12 months ]
    Blinded photographic evaluation which wound half resembles more closely the surrounding skin with regard to texture, redness, growth of hair, and pigmentation.

  7. Likert Scale Rating of Tolerability [ Time Frame: 2 to 4 weeks ]
    Participants and investigators were asked to evaluate the tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only (standard of care) on a 5-point Likert scale (treatment with Oleogel-S10 is much better tolerated, treatment with Oleogel-S10 is better tolerated, both treatments are equally well tolerated, non-adhesive wound dressing only is better tolerated, non-adhesive wound dressing only is much better tolerated).

  8. Pharmacokinetic (PK) Data (Number of Plasma Samples With Measurable Betulin Concentration) [ Time Frame: up to 4 weeks ]
    Systemic presence/concentration of betulin in blood plasma samples. Plasma samples were collected in weekly intervals and at the end of treatment (when wound closure was achieved or at Day 28). Samples were analysed in a central laboratory with a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 1 ng/mL.

  9. Pharmacokinetic (PK) Data (Plasma Betulin Concentration) [ Time Frame: up to 4 weeks ]
    Systemic presence/concentration of betulin in blood plasma samples - values for the number of samples with measurable values in samples above the lower limit of quantification (LLOQ) of 1 ng/mL

  10. Frequency of Adverse Events [ Time Frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier). ]
  11. Severity of Adverse Events [ Time Frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier). ]
    Adverse Events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) as being mild (NCI CTCAE Grade 1), moderate (NCI CTCAE Grade 2), severe (NCI CTCAE Grade 3), life-threatening (NCI CTCAE Grade 4) or death (NCI CTCAE Grade 5).

  12. Adverse Events by Relationship to Study Medication [ Time Frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier). ]
    Adverse events were assessed as being 'unlikely', 'possibly' or 'probably' related to study medication, 'not related' to study medication or the relationship to study medication was rated as 'unknown'.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants at least 18 years old who have provided written informed consent
  • Presenting a split-thickness skin graft donor site wound with a minimum size of 15 cm2 and with a minimum width of 3 cm.
  • Participant was able to understand the Informed Consent Form (ICF) provided and was prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing change and photo documentation every third or fourth day until both wound halves were closed (but no longer than 28 days after surgery).
  • Willing to perform all necessary wound dressing changes at the trial site. Also the participant needed to agree to return to site for 3 and 12 months follow-up visits.
  • Women of childbearing potential who were in the period between menarche and menopause needed to apply a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices [IUDs], sexual abstinence, or a vasectomized partner). Birth control method needed to have been applied for at least 1 monthly cycle prior to first administration of study drug, be maintained during the study treatment phase and continued for at least 30 days after the last administration of study drug. Sexually active, non-vasectomized men needed to use a barrier method (condoms) during the treatment phase of this clinical trial.

Exclusion Criteria:

  • Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety or efficacy.
  • A skin disorder that was chronic or currently active and which the Investigator considered would adversely affect the healing of the acute wounds or involved the areas to be examined in this trial.
  • A history of clinically significant hypersensitivity to any of the drugs, surgical dressings or excipients to be used in this trial.
  • Known multiple allergic disorders.
  • Taking, or have taken, any investigational drugs within 3 months prior to the screening visit.
  • Pregnant or breast feeding women were not allowed to participate in the study.
  • Inappropriate to participate in the study, for any reason, in the opinion of the investigator.
  • Mental incapacity or language barriers precluding adequate understanding the ICF or co-operation or willingness to follow study procedures.
  • Previous participation in this study.
  • Employee at the investigational site, relative or spouse of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01807650


Locations
Layout table for location information
France
CHU de Bordeaux
Bordeaux, France
Hôpital de la Conception
Marseille, France
CHU de Nantes
Nantes, France
Greece
KAT General Hospital of Attica
Athens, Greece
National University, "Andreas Syggros" Skin & Venereal Diseases Hospital
Athens, Greece
Aristotle University General Hospital
Thessaloniki, Greece
Latvia
Riga East University Hospital, Microsurgery Center
Riga, Latvia
Riga East University Hospital, State Burn Center
Riga, Latvia
Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Getafe
Madrid, Spain
Hopital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Universitario Rio Ortega
Valladolid, Spain
Hospital Miguel Servet
Zaragoza, Spain
Sponsors and Collaborators
Birken AG
Investigators
Layout table for investigator information
Principal Investigator: Juan Pedro Barret Nerin, MD Hospital Universitari Vall d´Hebron, Barcelona, Spain

Publications:
Layout table for additonal information
Responsible Party: Birken AG
ClinicalTrials.gov Identifier: NCT01807650     History of Changes
Other Study ID Numbers: BSG-12
2012-003390-26 ( EudraCT Number )
First Posted: March 8, 2013    Key Record Dates
Results First Posted: July 19, 2018
Last Update Posted: July 19, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Amryt Pharma ( Birken AG ):
Split-Thickness Skin Graft (STSG) donor site
Split-thickness skin graft
STSG
Wound healing
Skin grafting
Superficial wound
Partial-thickness wound
Time to wound closure
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries